Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.11
-1.3%
$20.05
$11.50
▼
$22.13
$7.36B1.242.43 million shs1.11 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$129.24
-4.7%
$165.57
$123.00
▼
$260.19
$6.80B0.86792,859 shs597,704 shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$32.55
-1.3%
$37.95
$25.90
▼
$43.49
$1.91B1893,690 shs422,099 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$102.11
+0.0%
$100.43
$53.38
▼
$111.86
$6.68B0.011.08 million shs681,884 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-2.37%-1.56%+7.67%+19.27%+85.43%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.25%-6.02%-14.98%-34.70%-7.56%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
-0.39%-2.43%-14.78%-13.55%-0.99%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.10%+0.84%+1.70%+2.13%+93.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.11
-1.3%
$20.05
$11.50
▼
$22.13
$7.36B1.242.43 million shs1.11 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$129.24
-4.7%
$165.57
$123.00
▼
$260.19
$6.80B0.86792,859 shs597,704 shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$32.55
-1.3%
$37.95
$25.90
▼
$43.49
$1.91B1893,690 shs422,099 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$102.11
+0.0%
$100.43
$53.38
▼
$111.86
$6.68B0.011.08 million shs681,884 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-2.37%-1.56%+7.67%+19.27%+85.43%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.25%-6.02%-14.98%-34.70%-7.56%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
-0.39%-2.43%-14.78%-13.55%-0.99%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.10%+0.84%+1.70%+2.13%+93.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.80
Moderate Buy$23.008.93% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.86
Moderate Buy$266.21105.98% Upside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
2.38
Hold$48.0047.49% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.21
Hold$107.445.22% Upside

Current Analyst Ratings Breakdown

Latest HRMY, AXSM, LNTH, and AMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetEqual Weight$249.00 ➝ $223.00
11/13/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
DowngradeStrong-Buy ➝ Hold
11/12/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Reiterated RatingBuy$55.00
11/10/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
DowngradeBuy (B) ➝ Hold (C+)
11/9/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
DowngradeBuy (B-) ➝ Hold (C+)
11/5/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOutperform$23.00 ➝ $25.00
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Reiterated RatingOverweight$21.00
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOverweight$24.00 ➝ $25.00
11/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetOutperform$284.00 ➝ $272.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingOutperform
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetBuy$256.00 ➝ $239.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.20B2.30$1.51 per share14.01$1.52 per share13.89
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M10.65N/AN/A$2.00 per share64.62
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$868.45M2.20$3.13 per share10.41$18.26 per share1.78
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.56B4.27$6.39 per share15.97$20.73 per share4.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.4250.2718.682.494.17%283.50%7.79%N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.06N/A35.31N/A-18.18%-198.73%-22.03%N/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$158.69M$3.0210.788.730.3518.05%18.55%13.24%N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$233.56M$4.0625.1518.14N/A17.28%29.26%15.40%N/A

Latest HRMY, AXSM, LNTH, and AMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.23$1.68+$0.45$0.33$355.74 million$389.91 million
11/4/2026Q3 2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$1.09$0.81-$0.28$0.81$272.05 million$268.92 million
11/3/2026Q3 2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.23$0.26+$0.03-$0.06N/A$862.68 million
11/2/2026Q3 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.6343-$0.25+$0.3843-$0.25$249.19 million$259.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
5.61
1.87
1.24
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.21
1.42
1.34
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.12
3.44
3.42
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.42
3.25
3.06

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
11.00%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500348.41 million288.14 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
92552.60 million41.76 millionOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
29358.72 million52.26 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1,19365.40 million64.29 millionOptionable

Recent News About These Companies

Lantheus' Q3 Adjusted Earnings, Revenue Rise
Lantheus Holdings Releases Q3 2026 Financial Results
Lantheus Holdings: Q3 earnings snapshot
Lantheus Reports Third Quarter 2026 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$21.11 -0.28 (-1.29%)
Closing price 03:58 PM Eastern
Extended Trading
$21.13 +0.02 (+0.08%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$129.24 -6.44 (-4.74%)
Closing price 03:59 PM Eastern
Extended Trading
$127.98 -1.27 (-0.98%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$32.54 -0.44 (-1.32%)
Closing price 03:58 PM Eastern
Extended Trading
$32.59 +0.05 (+0.14%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$102.11 +0.01 (+0.01%)
Closing price 03:59 PM Eastern
Extended Trading
$102.10 0.00 (0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.